GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Trevi Therapeutics Inc (NAS:TRVI) » Definitions » Price-to-Owner-Earnings

Trevi Therapeutics (Trevi Therapeutics) Price-to-Owner-Earnings : (As of May. 01, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Trevi Therapeutics Price-to-Owner-Earnings?

As of today (2024-05-01), Trevi Therapeutics's share price is $2.95. Trevi Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Trevi Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:


TRVI's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 32.2
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-01), Trevi Therapeutics's share price is $2.95. Trevi Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.29. Therefore, Trevi Therapeutics's PE Ratio for today is At Loss.

As of today (2024-05-01), Trevi Therapeutics's share price is $2.95. Trevi Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.29. Therefore, Trevi Therapeutics's PE Ratio without NRI for today is At Loss.


Trevi Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Trevi Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trevi Therapeutics Price-to-Owner-Earnings Chart

Trevi Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial - - - - -

Trevi Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Trevi Therapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, Trevi Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Trevi Therapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Trevi Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Trevi Therapeutics's Price-to-Owner-Earnings falls into.



Trevi Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Trevi Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=2.95/-0.33
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Trevi Therapeutics  (NAS:TRVI) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Trevi Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Trevi Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Trevi Therapeutics (Trevi Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
195 Church Street, 16th Floor, New Haven, CT, USA, 06510
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
Executives
Lisa Delfini officer: Chief Financial Officer C/O TREVI THERAPEUTICS, INC., 195 CHURCH STREET, FL. 14, NEW HAVEN CT 06510
Farrell Simon officer: Chief Commercial Officer C/O TREVI THERAPEUTICS, INC., 195 CHURCH STREET, FLOOR 14, NEW HAVEN CT 06510
David J Clark officer: Chief Medical Officer 131 HARTWELL AVE, LEXINGTON MA 02421
Tpg Gp A, Llc 10 percent owner 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
Scott D Sandell 10 percent owner
Carmen Chang 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
New Enterprise Associates 16, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Paul Edward Walker director 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Forest Baskett 10 percent owner
Peter W. Sonsini 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Florence Anthony A. Jr. 10 percent owner 5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Ali Behbahani 10 percent owner 5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Mohamad Makhzoumi 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Jon Winkelried 10 percent owner C/O GOLDMAN, SACHS & CO., 85 BROAD STREET, NEW YORK NY 10004
Christopher Galletta officer: See Remarks 195 CHURCH STREET, FLOOR 14,, NEW HAVEN CT 06510